A continuously updated index of peer-reviewed studies on medicinal cannabis and cannabinoids — sourced from PubMed, summarised in plain English, and organised by the body system they affect. Pick a tile to filter, or search the full library below.
This registered trial is investigating whether transcranial direct current stimulation (tDCS) can help reduce cannabis use in 110 patients with co-occurring schizophrenia and cannabis use disorder. The study aims to measure changes in cannabis consumption, craving, addiction severity, schizophrenia symptoms, and overall functioning.
This registered clinical trial is investigating whether a combined intervention can help young adults who experience problems with alcohol and cannabis use, as well as sleep difficulties, to reduce these issues. The study aims to recruit 800 participants to evaluate the effectiveness of this intervention.
This registered trial is investigating carcinogen and toxicant exposure in young adults who use both e-cigarettes and cannabis. The study will measure nicotine, cannabis, and toxicant levels in blood and urine, alongside assessing user behaviors. The goal is to understand the impact of co-using these products in this population.
This is a registered, ongoing, randomized controlled trial investigating whether plant-derived cannabidiol (CBD) can reduce cannabis concentrate use, subjective effects of cannabis, or cannabis cravings in regular cannabis concentrate users who are not seeking to quit. Participants will receive either 200mg/400mg of CBD or a placebo daily for four weeks.
This registered trial aims to investigate the potential harm-reducing effects of hemp-derived CBD in young adult cannabis users. Participants will be randomized to receive CBD or placebo, with a focus on their regular cannabis use patterns in a naturalistic setting.
This study aims to determine if pregnenolone can reverse acute cannabis intoxication and its associated symptoms in healthy adults. It is a placebo-controlled, within-subject crossover study currently recruiting participants. The goal is to lay the groundwork for future research into CB1-receptor NAM medications and validate pregnenolone as a treatment.
This registered clinical trial aims to explore how acute THC administration affects reward processing differently in men and women with cannabis use disorder. Researchers will use neuroimaging to examine brain changes related to reward anticipation after participants receive either THC or a placebo. The study seeks to understand sex-specific neurobehavioral responses to THC.
This registered clinical trial aims to explore how acute cannabis exposure affects men and women differently. Researchers hope to identify the underlying biological mechanisms behind any observed gender-specific responses. The study is currently recruiting participants.
This study is investigating the effects of cannabidiol (CBD) and tetrahydrocannabinol (THC) on the microbiome and neuroinflammation in individuals with HIV. It aims to understand how cannabis use and HIV interact to affect the brain and inflammation markers. The study is currently recruiting and involves different treatment sequences over six weeks, including physical exams and blood tests.
This study is investigating whether long-term use of cannabidiol (CBD) oral solution could lead to chronic liver damage or scarring in patients being treated for severe seizure disorders.
This registered trial aims to assess the effectiveness and feasibility of using oral cannabis extracts, specifically CBD and THC, for managing pain associated with osteoarthritis of the hip and/or knee. It compares these cannabinoids against a placebo to evaluate their impact on pain interference.
This registered trial investigates whether a single 600mg dose of CBD can enhance the extinction of conditioned fear responses in college students with social anxiety, compared to a placebo. Participants will undergo a fear conditioning paradigm, followed by either CBD or placebo, and their fear extinction will be measured.
This randomized, placebo-controlled trial investigated the effect of cannabigerol (CBG) on sleep and quality of life in Veterans. While CBG was well tolerated and generally improved sleep, there was no statistically significant difference between the CBG and placebo groups for sleep quality, PTSD symptoms, or quality of life.
This randomized controlled trial investigated the effectiveness of oral cannabidiol (CBD) for treating myofascial pain disorder in the temporomandibular region. It compared CBD to a placebo (hemp seed oil) to see if it could reduce pain and improve jaw function over a three-month period.
This is a registered clinical trial investigating a marijuana-based compound, primarily CBD with a small amount of THC, for treating anxiety in autistic adults. Participants will take the drug or a placebo daily for 8 weeks, recording their feelings to assess changes in anxiety symptoms. The study aims to determine the efficacy and safety of the compound for this population.
This is a randomized, placebo-controlled study investigating how different doses of CBD affect pain and opioid cravings in outpatients with opioid use disorder who are already receiving medication for their condition.
This is an active, not yet recruiting, pilot clinical trial investigating the therapeutic effects of a full-spectrum cannabis extract with varying doses of CBD and THC on fibromyalgia symptoms in cisgender women. The study aims to determine if cannabinoids can reduce pain, fatigue, and other symptoms while improving quality of life, with dose adjustments based on clinical response over six months.
This registered trial is investigating the effects of THC, CBD, and placebo on cognitive function, endocannabinoid levels, and dopamine activity in individuals with and without HIV. The study aims to clarify the impact of cannabis on decision-making, inhibition, and other cognitive behaviors in this population, considering both recreational and medicinal use.
This registered trial is investigating the safety and effectiveness of a fixed-dose cannabis inhaler containing THC as an add-on treatment for diabetic peripheral neuropathic pain. Participants will receive different doses of THC or a placebo, with pain intensity being the primary measure at 15 weeks.
This registered trial is investigating the impact of reduced cannabis use on the daily functioning of military veterans with Posttraumatic Stress Disorder (PTSD). The study aims to gather real-time data on how changes in cannabis consumption affect veterans' functional outcomes. The central hypothesis is that decreased cannabis use will lead to improved functional outcomes in this population.
This review article explores voltage-gated sodium channels in the nervous system, focusing on their role in neurological disorders like epilepsy, migraine, and autism. It discusses various therapeutic interventions, including conventional sodium channel blockers, newer drugs like gabapentin and cannabidiol, and advances in gene therapy. The goal is to compare different treatment strategies and envision future personalized medicine for ion channel diseases.
This scoping review investigates unintentional exposures to psychoactive cannabis products in adults, focusing on those seeking medical care. It describes symptoms, common product types, and recovery times for 84 reported cases. The review aims to guide clinicians in identifying such ingestions due to their varied presentations.
This observational study investigated how the combined use of cannabis, alcohol, and tobacco affects sleep health in adults. Researchers found that polysubstance use negatively impacted sleep quality and satisfaction, while hazardous cannabis use was linked to increased sleepiness. The findings suggest that using multiple substances is detrimental to sleep health.
This study surveyed French healthcare providers regarding their acceptance of cannabis and CBD for Parkinson's disease. It found that CBD was more accepted than cannabis, and physicians were generally less accepting of both due to perceived lack of evidence. The findings suggest a need for more robust scientific evidence and training if cannabis-based products are to be authorized for PD in France.
This registered clinical trial is investigating the effectiveness and safety of a full-spectrum cannabis extract, YCJ-01, in patients with refractory epilepsy associated with Tuberous Sclerosis Complex. The primary objective is to evaluate changes in seizure frequency and adverse events.
This study is testing a text-delivered counselling program aimed at helping young adults (aged 18-25) reduce or stop their cannabis use. It focuses on individuals with mild, moderate, or severe cannabis use disorder. The study is currently active but not recruiting new participants.
This registered trial investigates the impact of CBD on sleep quality in individuals who engage in late-evening high-intensity interval training. Participants will receive either CBD or a placebo in a randomized, double-blind crossover design. Sleep will be monitored using polysomnography to assess potential improvements.
This systematic review evaluated the effectiveness and safety of cannabis-based medicines for chemotherapy-induced nerve pain. It found insufficient evidence to recommend them for routine use, with no significant improvement in pain or quality of life observed in controlled trials. Larger, more rigorous studies are needed.
This study investigated how social and substance use-related risks, including cannabis use, are associated with the duration of untreated psychosis (DUP) in patients with psychotic disorders. Researchers identified distinct groups of patients based on these risk factors and examined their impact on how long psychosis goes untreated. The findings highlight the importance of considering multiple social and substance use factors when addressing DUP.
This retrospective study investigated whether cannabis intoxication affected the nutritional status of adult burn patients with less than 20% total body surface area (TBSA) burns. Researchers compared 76 cannabis-positive patients to 76 cannabis-negative controls, analysing markers like prealbumin and albumin levels. The study found no significant impact of cannabis on nutritional status in this patient group.
Showing 30 of 354